Cargando…

Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol

BACKGROUND: Medication errors, adverse drug events, and nonadherence are the predominant causes of graft loss in kidney transplant recipients and lead to increased healthcare utilization. Research has demonstrated that clinical pharmacists have the unique education and training to identify these eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, James N, Treiber, Frank, McGillicuddy, John, Gebregziabher, Mulugeta, Taber, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856926/
https://www.ncbi.nlm.nih.gov/pubmed/29500161
http://dx.doi.org/10.2196/resprot.9078
_version_ 1783307371885363200
author Fleming, James N
Treiber, Frank
McGillicuddy, John
Gebregziabher, Mulugeta
Taber, David J
author_facet Fleming, James N
Treiber, Frank
McGillicuddy, John
Gebregziabher, Mulugeta
Taber, David J
author_sort Fleming, James N
collection PubMed
description BACKGROUND: Medication errors, adverse drug events, and nonadherence are the predominant causes of graft loss in kidney transplant recipients and lead to increased healthcare utilization. Research has demonstrated that clinical pharmacists have the unique education and training to identify these events early and develop strategies to mitigate or prevent downstream sequelae. In addition, studies utilizing mHealth interventions have demonstrated success in improving the control of chronic conditions that lead to kidney transplant deterioration. OBJECTIVE: The goal of the prospective, randomized TRANSAFE Rx study is to measure the clinical and economic effectiveness of a pharmacist-led, mHealth-based intervention, as compared to usual care, in kidney transplant recipients. METHODS: TRANSAFE Rx is a 12-month, parallel, two-arm, 1:1 randomized controlled clinical trial involving 136 participants (68 in each arm) and measuring the clinical and economic effectiveness of a pharmacist-led intervention which utilizes an innovative mobile health application to improve medication safety and health outcomes, as compared to usual posttransplant care. RESULTS: The primary outcome measure of this study will be the incidence and severity of MEs and ADRs, which will be identified, categorized, and compared between the intervention and control cohorts. The exploratory outcome measures of this study are to compare the incidence and severity of acute rejections, infections, graft function, graft loss, and death between research cohorts and measure the association between medication safety issues and these events. Additional data that will be gathered includes sociodemographics, health literacy, depression, and support. CONCLUSIONS: With this report we describe the study design, methods, and outcome measures that will be utilized in the ongoing TRANSAFE Rx clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03247322: https://clinicaltrials.gov/ct2/show/NCT03247322 (Archived by WebCite at http://www.webcitation.org/6xcSUnuzW)
format Online
Article
Text
id pubmed-5856926
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-58569262018-03-26 Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol Fleming, James N Treiber, Frank McGillicuddy, John Gebregziabher, Mulugeta Taber, David J JMIR Res Protoc Protocol BACKGROUND: Medication errors, adverse drug events, and nonadherence are the predominant causes of graft loss in kidney transplant recipients and lead to increased healthcare utilization. Research has demonstrated that clinical pharmacists have the unique education and training to identify these events early and develop strategies to mitigate or prevent downstream sequelae. In addition, studies utilizing mHealth interventions have demonstrated success in improving the control of chronic conditions that lead to kidney transplant deterioration. OBJECTIVE: The goal of the prospective, randomized TRANSAFE Rx study is to measure the clinical and economic effectiveness of a pharmacist-led, mHealth-based intervention, as compared to usual care, in kidney transplant recipients. METHODS: TRANSAFE Rx is a 12-month, parallel, two-arm, 1:1 randomized controlled clinical trial involving 136 participants (68 in each arm) and measuring the clinical and economic effectiveness of a pharmacist-led intervention which utilizes an innovative mobile health application to improve medication safety and health outcomes, as compared to usual posttransplant care. RESULTS: The primary outcome measure of this study will be the incidence and severity of MEs and ADRs, which will be identified, categorized, and compared between the intervention and control cohorts. The exploratory outcome measures of this study are to compare the incidence and severity of acute rejections, infections, graft function, graft loss, and death between research cohorts and measure the association between medication safety issues and these events. Additional data that will be gathered includes sociodemographics, health literacy, depression, and support. CONCLUSIONS: With this report we describe the study design, methods, and outcome measures that will be utilized in the ongoing TRANSAFE Rx clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03247322: https://clinicaltrials.gov/ct2/show/NCT03247322 (Archived by WebCite at http://www.webcitation.org/6xcSUnuzW) JMIR Publications 2018-03-02 /pmc/articles/PMC5856926/ /pubmed/29500161 http://dx.doi.org/10.2196/resprot.9078 Text en ©James N Fleming, Frank Treiber, John McGillicuddy, Mulugeta Gebregziabher, David J Taber. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 02.03.2018. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Fleming, James N
Treiber, Frank
McGillicuddy, John
Gebregziabher, Mulugeta
Taber, David J
Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol
title Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol
title_full Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol
title_fullStr Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol
title_full_unstemmed Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol
title_short Improving Transplant Medication Safety Through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention: TRANSAFE Rx Study Protocol
title_sort improving transplant medication safety through a pharmacist-empowered, patient-centered, mhealth-based intervention: transafe rx study protocol
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856926/
https://www.ncbi.nlm.nih.gov/pubmed/29500161
http://dx.doi.org/10.2196/resprot.9078
work_keys_str_mv AT flemingjamesn improvingtransplantmedicationsafetythroughapharmacistempoweredpatientcenteredmhealthbasedinterventiontransaferxstudyprotocol
AT treiberfrank improvingtransplantmedicationsafetythroughapharmacistempoweredpatientcenteredmhealthbasedinterventiontransaferxstudyprotocol
AT mcgillicuddyjohn improvingtransplantmedicationsafetythroughapharmacistempoweredpatientcenteredmhealthbasedinterventiontransaferxstudyprotocol
AT gebregziabhermulugeta improvingtransplantmedicationsafetythroughapharmacistempoweredpatientcenteredmhealthbasedinterventiontransaferxstudyprotocol
AT taberdavidj improvingtransplantmedicationsafetythroughapharmacistempoweredpatientcenteredmhealthbasedinterventiontransaferxstudyprotocol